Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
HIV
cobicistat
elvitegravir
pharmacokinetics
pregnancy
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
17 12 2020
17 12 2020
Historique:
received:
24
02
2020
accepted:
23
04
2020
pubmed:
25
4
2020
medline:
29
4
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.
Identifiants
pubmed: 32330231
pii: 5824808
doi: 10.1093/cid/ciaa488
pmc: PMC7744974
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Quinolones
0
elvitegravir
4GDQ854U53
Banques de données
ClinicalTrials.gov
['NCT00825929']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e714-e717Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.